{
    "clinical_study": {
        "@rank": "163066", 
        "arm_group": [
            {
                "arm_group_label": "Remifentanil+Morphine", 
                "arm_group_type": "Active Comparator", 
                "description": "Morphine(M) Remifentanil+Morphine(MR)"
            }, 
            {
                "arm_group_label": "IV morphine PCA", 
                "arm_group_type": "Active Comparator", 
                "description": "IV remifentanil+morphine PCA"
            }
        ], 
        "brief_summary": {
            "textblock": "Background; Post-thoracotomy pain remains a major problem. This double-blind, randomized\n      study tested the effects of coadministration of patient controlled remifentanil+morphine\n      combination on postthoracotomy pain, analgesic consumption and side effects compared with\n      morphine PCA alone"
        }, 
        "brief_title": "Intravenous Remifentanil Plus Morphine or Morphine Alone for Postthoracotomy Pain", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Pain", 
        "detailed_description": {
            "textblock": "Methods; Sixty patients were allocated randomly to receive an intravenous patient-controlled\n      analgesia with morphine alone (M), or morphine plus remifentanil (MR), in a double-blind\n      manner. Postoperatively patients were allowed to use bolus doses of morphine (0.2 mg kg-1)\n      or morphine (0.2 mg kg-1) plus remifentanil (0.2 \u00b5g kg-1) mixture every 10 min without a\n      background infusion. Pain, discomfort, sedation scores, total and bolus patient-controlled\n      morphine consumption, rescue analgesic requirement and side-effects were recorded for up to\n      24 h after the start of patient-controlled analgesia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  60 ASA physical status I-III patients, between the ages of 18 and 59 years, scheduled\n             for elective thoracotomy surgery with general anaesthesia were included in this study\n\n        Exclusion Criteria:\n\n          -  severe hepatorenal disease history, sensitivity or contraindication to morphine and\n             remifentanil, chronic pain (defined as regular use of opioid analgesics for > 3\n             months), drug or alcohol abuse and contraindication to administration of PCA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "59 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830296", 
            "org_study_id": "MDHTRKTN13"
        }, 
        "intervention": {
            "arm_group_label": [
                "Remifentanil+Morphine", 
                "IV morphine PCA"
            ], 
            "description": "Morphine, Remifentanil+Morphine", 
            "intervention_name": "Remifentanil+morphine", 
            "intervention_type": "Drug", 
            "other_name": [
                "Morphine Group (M)", 
                "Remifentanil+Morphine Group (MR)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Morphine", 
                "Remifentanil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Postthoracotomy pain,", 
            "patient controlled analgesia,", 
            "remifentanil and", 
            "morphine."
        ], 
        "lastchanged_date": "April 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Adana", 
                    "country": "Turkey", 
                    "zip": "01330"
                }, 
                "name": "Hakk\u0131 Unlugenc"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "official_title": "COADMINISTRATION OF INTRAVENOUS REMIFENTANIL AND MORPHINE FOR POSTTHORACOTOMY PAIN; COMPARISON WITH IV MORPHINE ALONE", 
        "overall_official": {
            "affiliation": "Cukurova University, Department of Anaesthesiology", 
            "last_name": "Mediha Turktan, Assist Prof", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "As aim of this study was to evaluate the effects of remifentanil addition to morphine for i.v. PCA on analgesic consumption, the primary endpoint was defined as morphine consumption at 24 hour.", 
            "measure": "COADMINISTRATION OF INTRAVENOUS REMIFENTANIL AND MORPHINE FOR POSTTHORACOTOMY PAIN; COMPARISON WITH IV MORPHINE ALONE", 
            "safety_issue": "No", 
            "time_frame": "Two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830296"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cukurova University", 
            "investigator_full_name": "Hakki Unlugenc", 
            "investigator_title": "Prof Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Cukurova University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cukurova University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}